Statements (44)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
gptkb:skincare_product
mucous membranes |
| gptkbp:associated_with |
gptkb:Insurance_Company
thymoma |
| gptkbp:caused_by |
autoimmune response
|
| gptkbp:clinical_trial |
skin lesions
oral lesions Nikolsky sign positive |
| gptkbp:complications |
gptkb:healthcare_organization
malnutrition dehydration |
| gptkbp:current_use |
gptkb:pemphigus_foliaceus
|
| gptkbp:first_described_by |
1930s
|
| gptkbp:historical_significance |
first autoimmune blistering disease described
influenced dermatology research |
| https://www.w3.org/2000/01/rdf-schema#label |
pemphigus vulgaris
|
| gptkbp:is_a_route_for |
antibodies against desmogleins
loss of cell adhesion |
| gptkbp:is_popular_in |
rare
|
| gptkbp:public_awareness |
gptkb:Pemphigus_Awareness_Month
September |
| gptkbp:research_focus |
biomarkers
genetic studies new therapies understanding pathogenesis |
| gptkbp:risk_factor |
HLA-DQ B1*03:01
HLA-DR B1*04:02 |
| gptkbp:scholarships |
educational resources available
support groups available |
| gptkbp:social_responsibility |
variable
biopsy can be life-threatening more common in women direct immunofluorescence typically diagnosed in middle age |
| gptkbp:symptoms |
blisters
painful sores |
| gptkbp:treatment |
corticosteroids
immunosuppressants chronic condition remission possible |
| gptkbp:bfsParent |
gptkb:Rituxan
|
| gptkbp:bfsLayer |
4
|